NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis $27.55 -0.66 (-2.34%) (As of 03:37 PM ET) Add Compare Share Share Today's Range$27.48▼$28.3050-Day Range$20.34▼$28.2152-Week Range$18.94▼$44.64Volume308,903 shsAverage Volume756,074 shsMarket Capitalization$1.31 billionP/E RatioN/ADividend YieldN/APrice Target$42.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get AtriCure alerts: Email Address AtriCure MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside54.1% Upside$42.44 Price TargetShort InterestBearish7.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.89Based on 2 Articles This WeekInsider TradingSelling Shares$84,245 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.77) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.17 out of 5 starsMedical Sector334th out of 927 stocksSurgical & Medical Instruments Industry42nd out of 101 stocks 4.5 Analyst's Opinion Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtriCure has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AtriCure's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.52% of the outstanding shares of AtriCure have been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in AtriCure has recently decreased by 1.65%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATRC. Previous Next 2.2 News and Social Media Coverage News SentimentAtriCure has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for AtriCure this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for ATRC on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $84,245.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($0.77) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -34.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -34.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AtriCure's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Brownstone Research My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.Just click here to register. About AtriCure Stock (NASDAQ:ATRC)AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Read More ATRC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRC Stock News HeadlinesAugust 20, 2024 | insidertrades.comAtriCure, Inc. (NASDAQ:ATRC) Director Maggie Yuen Sells 3,500 SharesSeptember 16 at 1:37 AM | americanbankingnews.comAtriCure (NASDAQ:ATRC) Upgraded to Hold at StockNews.comSeptember 16, 2024 | Brownstone Research (Ad) My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.September 9, 2024 | americanbankingnews.comAtriCure, Inc. (NASDAQ:ATRC) Receives $42.44 Consensus Price Target from AnalystsAugust 27, 2024 | finance.yahoo.comAtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ DeviceAugust 22, 2024 | finance.yahoo.comAtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial FibrillationAugust 19, 2024 | bizjournals.comAtriCure leadership explains $45M investment in Greater Cincinnati HQAugust 15, 2024 | finance.yahoo.comTop 3 Undervalued Small Caps With Insider Buys To Watch In United States August 2024September 16, 2024 | Brownstone Research (Ad) My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.August 15, 2024 | markets.businessinsider.comAtricure’s Market Strength and Innovation Justify Buy RatingAugust 12, 2024 | finance.yahoo.comATRC Aug 2024 17.500 put (ATRC240816P00017500)August 2, 2024 | finance.yahoo.comUS$39.89: That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After Its Latest ResultsAugust 1, 2024 | markets.businessinsider.comAtricure’s Stable Financials and Strategic Growth Outlook Justify Buy RatingJuly 31, 2024 | seekingalpha.comAtriCure, Inc. (ATRC) Q2 2024 Earnings Call TranscriptJuly 31, 2024 | markets.businessinsider.comAtriCure’s Growth Prospects and Buy Rating Despite Short-Term ChallengesJuly 31, 2024 | msn.comAtriCure, Inc. (NASDAQ:ATRC) Q2 2024 Earnings Call TranscriptJuly 31, 2024 | stockhouse.comAtriCure Reports Second Quarter 2024 Financial ResultsJuly 30, 2024 | investorplace.comATRC Stock Earnings: AtriCure Meets EPS, Beats Revenue for Q2 2024See More Headlines Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/30/2024Today9/16/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ATRC CUSIP04963C20 CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,200Year Founded2000Price Target and Rating Average Stock Price Target$42.44 High Stock Price Target$60.00 Low Stock Price Target$26.00 Potential Upside/Downside+49.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,440,000.00 Net Margins-9.33% Pretax Margin-9.13% Return on Equity-8.39% Return on Assets-6.45% Debt Debt-to-Equity Ratio0.16 Current Ratio4.13 Quick Ratio2.93 Sales & Book Value Annual Sales$429.95 million Price / Sales3.14 Cash FlowN/A Price / Cash FlowN/A Book Value$9.84 per share Price / Book2.88Miscellaneous Outstanding Shares47,588,000Free Float46,065,000Market Cap$1.35 billion OptionableOptionable Beta1.43 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Michael H. Carrel (Age 53)CEO, President & Director Comp: $2.01MMs. Angela L. Wirick CPA (Age 46)Chief Financial Officer Comp: $841.54kMr. Douglas J. Seith (Age 58)Chief Operating Officer Comp: $1.2MMr. Salvatore Privitera J.D. (Age 57)Chief Technical Officer Comp: $758.8kMr. Karl S. Dahlquist CCEP (Age 53)J.D., Chief Legal Officer Comp: $762.39kDr. Vinayak Doraiswamy Ph.D. (Age 52)Chief Scientific Officer Comp: $777.66kValerie Storch-WillhausVice President of Corporate Marketing & CommunicationsMr. Justin J. Noznesky (Age 46)Chief Marketing & Strategy Officer Comp: $644.73kMs. Deborah Yount (Age 58)Chief Human Resources Officer Comp: $498.36kMore ExecutivesKey CompetitorsCardiovascular SystemsNASDAQ:CSIIAtrionNASDAQ:ATRINuVasiveNASDAQ:NUVAPulmonxNASDAQ:LUNGInovio PharmaceuticalsNASDAQ:INOView All CompetitorsInsiders & InstitutionsTruist Financial CorpBought 1,842 shares on 8/21/2024Ownership: 0.032%Algert Global LLCSold 9,918 shares on 8/16/2024Ownership: 0.191%AQR Capital Management LLCBought 16,251 shares on 8/15/2024Ownership: 0.123%The Manufacturers Life Insurance Company Bought 1,429 shares on 8/15/2024Ownership: 0.052%Deerfield Management Company L.P. Series CSold 3,672 shares on 8/15/2024Ownership: 0.036%View All Insider TransactionsView All Institutional Transactions ATRC Stock Analysis - Frequently Asked Questions How have ATRC shares performed this year? AtriCure's stock was trading at $35.69 at the start of the year. Since then, ATRC stock has decreased by 22.8% and is now trading at $27.55. View the best growth stocks for 2024 here. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings results on Tuesday, July, 30th. The medical device company reported ($0.17) earnings per share for the quarter, meeting the consensus estimate of ($0.17). The company's quarterly revenue was up 15.2% on a year-over-year basis. Does AtriCure have any subsidiaries? AtriCure subsidiaries include these companies: SentreHEART. Who are AtriCure's major shareholders? Top institutional shareholders of AtriCure include First Light Asset Management LLC (4.13%), Hood River Capital Management LLC (3.73%), Millennium Management LLC (2.00%) and Fiera Capital Corp (1.93%). Insiders that own company stock include Salvatore Privitera, Justin J Noznesky, Karl S Dahlquist, Vinayak Doraiswamy, Tonya Austin, Karen Prange, Maggie Yuen, Angela L Wirick and Mark A Collar. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT) and Neurocrine Biosciences (NBIX). This page (NASDAQ:ATRC) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.